ahstilde

Facebook innovation is their ads algo. They copy existing consumer success (which is incredibly difficult to create), and then execute it incredibly well.

ahstilde

2 ay öncediscuss

my entire thesis behind oro, my personal coding harness: https://github.com/mraakashshah/oro

ahstilde

3 ay öncediscuss

yup! When i did an analysis last month, GitHub is up 89.3% on weekdays and 96.5% on weekends. Incidents touch 62% of weekdays and 11% of weekends. Claude shows the same pattern: 92.5% weekday, 97.8% weekend. Tuesday through Thursday is the danger zone. Sunday is practically a different service.

https://www.aakash.io/tech-chase/github-and-claude-are-down-...

ahstilde

4 ay öncediscuss

buy off the shelf: https://archil.com/

ahstilde

4 ay öncediscuss

github is at one nine, basically: https://news.ycombinator.com/item?id=47428035

ahstilde

4 ay öncediscuss

yeah, between github and claude they're's an outage 75% of the time: https://www.aakash.io/tech-chase/github-and-claude-are-down-...

ahstilde

6 ay öncediscuss

https://github.com/finbarr/yolobox/

ahstilde

7 ay öncediscuss

I think your best bet is first curing your allergies. That's what I've been working on for 5 years: www.wyndly.com

ahstilde

8 ay öncediscuss

i do wish i could vibe code payments. stripe is good but LLMs need help.

ahstilde

9 ay öncediscuss

I totally agree. I actually started Wyndly (https://www.wyndly.com/) because I realized I was poisoning myself with antihistamines every single day for my allergies. I did the research, and antihistamines are know to cause anxiety, depression, weight gain, and brain fog!

I applied for YC. We got in!

And now we're chipping away at this corner of human health: treating the root cause of allergies with protein exposure therapy (allergy immunotherapy) instead of covering up allergy symptoms with ineffective (and, it turns out, dangerous) antihistamines.

ahstilde

9 ay öncediscuss

this matches our personal experience, too

ahstilde

10 ay öncediscuss

why is spanish so distributed?

ahstilde

10 ay öncediscuss

So you were heads-down building for a year!

ahstilde

geçen yıldiscuss

> just for fun (but, of course, pay them for their work).

Doing things for fun isn't in Google's remit

ahstilde

geçen yıldiscuss

This is called product-channel fit. It's great the writer recognized how to capture the demand from a new acquisition channel.

ahstilde

geçen yıldiscuss

very cool! What's the biggest thing you learned from Forward that you're applying here?

ahstilde

geçen yıldiscuss

Wyndly | Physician - Synchronous Telehealth - 1099 / Remote | https://www.wyndly.com

Join Wyndly in revolutionizing allergy care through telemedicine. We're transforming how millions access effective allergy treatment, making it both convenient and affordable. Our physicians find fulfillment in providing life-changing care while maintaining work-life balance.

Role Details: Remote, 1099 contractor position Multi-state licensed physician (ideal states: CA/TX/FL/NY/PA/IL/OH/GA/NC/MI) Preferred specialities (but not required): Family Medicine, Internal Medicine, Emergency Medicine, Allergy, ENT, Pulmonology Flexible scheduling with ability to set your own hours (preference for candidates able to provide over 10 hours per week)

Why Wyndly?

    Dedicated Clinical Support: Our operations team handles administrative tasks, prescription management, and patient communication, letting you focus solely on patient care
    Streamlined Workflow: Purpose-built EMR and protocols designed for allergy care
    Practice Focus: Exclusively allergy care using immunotherapy with SLIT drops and FDA-approved tablets
    Low-Risk Environment: No controlled substances, no addictive substances, minimal malpractice risk
    Physician-Led: Join a company that puts medical expertise first
    Equity Opportunity: All current physicians hold equity shares
    Full Coverage: Malpractice insurance and tail coverage provided
    Backed by Y Combinator and leading healthcare investors

Our physicians appreciate practicing medicine without administrative burden while making a significant impact on patients' quality of life. Join us in bringing innovative allergy care to millions.

Apply: https://app.dover.com/apply/Wyndly/7098c610-0e55-4bbb-b14e-b...

ahstilde

geçen yıldiscuss

> I really need a business partner to keep me focused on features people actually want.

Why can't you do this yourself?

ahstilde

geçen yıldiscuss

So you want a worse floodlight at a higher price because of government protection?

ahstilde

geçen yıldiscuss

I run a YC-backed tech-superpowered healthcare company, Wyndly [1]. I wanted to cure allergies, but then I realized that permanent allergy relief was already possible with allergy immunotherapy, which is compounded.

A compounded medicine is one which is made to order for the specific patient, versus being packaged in a factory en mass. It's almost like "making your own generic". In allergy, compounding is used to create custom allergy trigger mixes which are then used to build tolerance through allergy shots or under-the-tongue allergy drops. Compounding is also used a ton in skincare.

I've been following the GLP-1 and compounding conversation very closely, as the marketing and the operations have had secondary effects on Wyndly.

This specific action by Eli Lilly is a different tact then before. I suspect it may be more successful, too, because it's focused on protecting patients instead of protecting profits.

Look, Eli Lilly wants to defend their patent. They want to be the only people who can sell the drug they developed, its tirzepatide medications (Mounjaro and Zepbound).

In 2023 [2], EL went after providers who were selling compounded versions of their drugs, by going after deceptive marketing that was misusing their brand name. That's understandable. If a patient thinks they're getting Mounjaro, and they're not, that's fraud.

In 2024 [3], EL started going after the compounding pharmacies by sending hundreds of cease-and-desists. This was in sync with the FDA declaring the tirzepatide shortage over, allowing EL to defend its patent.

Now (2025), we're seeing a new evolution of the strategy. Here, EL is claiming that 4 companies, Mochi Health, Fella & Delilah Health (YC), Willow Health, and Henry Meds, are effectively practicing medicine incorrectly. This is what took down Cerebral [4] and Done ADHD [5].

In short, EL is saying "the businesses, not individual doctors, are changing the medicine, which is means the business is practicing medicine en masse, instead of through personalized provider-patient relationships."

Mochi: EL “switched dosages and prescriptions for patients en masse at least five times—with corporate interests, rather than doctor decisionmaking—driving the changes.”

Fella & Delilah: EL claims that Fella & Delilah Health switched all of its patients from a compounded tirzepatide product with no additives to a version containing untested amino acid additives late last year.

Henry Meds: EL accuses the company of “creating the false impression” that clinical trials have confirmed the effectiveness of its drugs, “materially omitting that no such clinical trial data exists.”

Willow Health: EL alleges false marketing of “custom-prepared” for patients despite being mass-produced.

All in all, this would be a violation Corporate Practice of Medicine Doctrine, which is a patchwork of laws that basically says: providers practice medicine and make the final calls on patient needs, not businesses.

Interesting stuff, honestly.

[1] https://www.wyndly.com/ [2] https://www.fiercepharma.com/pharma/lilly-expands-its-clampd... [3] https://www.wired.com/story/crackdown-compounded-glp-1-lilly... [4] https://www.justice.gov/usao-edny/pr/telehealth-company-cere... [5] https://www.additudemag.com/done-adhd-stimulant-medication-s...

Submissions

Code Slop Isn't a Model Problem, It's a Harness Problem

GitHub and Claude Are Down Three Out of Four Days

Wyndly (YC W21) Grew a Allergy Business on Reddit and YouTube

Real-Time Messaging: Speed and Context

Comparing AI Unit Test Generators: Tusk vs. Cursor Agent vs. Claude Code

Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs

AI Voice to Text for macOS and iOS

Google Q3 earnings call: CEO's remarks

[untitled]

[untitled]

Tasks and Metatasks do I need to bake a cake, or build a cake factory?

[untitled]

YC Cofounder Trevor Blackwell's Growth Calculator

Bounce Doctor – A free tool to check your email deliverability

Google cuts jobs across engineering, hardware teams for efficiency

[untitled]

Use Dependency Rejection to Beat Procrastination

We Sold Our Startup and Filmed Everything [video]

‘Monk mode’ is the ‘new’ trend to improve your attention span

Alumni Poll: The most valuable part of YC is the community

comments